2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl bromide

We are 2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl bromide CAS:81058-27-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl bromide
CAS.NO:81058-27-7
Synonyms:
Tetrakis(2,2-Dimethylpropanoate)-α-D-Glucopyranosyl Bromide
2,3,4,6-Tetra-O-Pivaloyl-α-D-Glucopyranosyl Bromide
2,3,3-Trimethyl-5-Chloro-3H-Indole
2,3,4,6-Tetra-O-Pivaloyl-alpha-D-Glucopyranosyl Bromide

Molecular Formula:C26H43BrO9
Molecular Weight:579.51800

Physical and Chemical Properties:
Density:1.22g/cm3
Boiling point: 530.5ºC at 760 mmHg
Melting point: /
Flash point: 274.6ºC
Refractive index: 1.494

Specification:
Appearance:white powder
Purity:≥99%
Moisture Content: ≤0.5%
Impurity: ≤0.1%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Dapagliflozin CAS:461432-26-8
Intermediates of Dapagliflozin Propanediol Monohydrate CAS:960404-48-2

2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl bromide


Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.3,5-Difluoropyridine At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.2369-19-9 It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.137654-21-8 It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.

Related Products
Product Name
4-Chloro-3-fluoronitrobenzene View Details
Iminodiacetonitrile View Details
(Z)-2-(2-Aminothiazol-4-yl)-2-(tert-butoxycarbonylmethoxyimino)acetic acid View Details
(3S,4R)-4-Acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one manufacturer Trichloro(3,3,3-trifluoropropyl)silane manufacturer 2-Methoxybenzonitrile manufacturer Hydroquinone manufacturer 1-phenyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzimidazole manufacturer